GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » EBIT

Hualan Biological Engineering (SZSE:002007) EBIT : ¥1,967 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering EBIT?

Hualan Biological Engineering's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥333 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,967 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hualan Biological Engineering's annualized ROC % for the quarter that ended in Mar. 2024 was 7.60%. Hualan Biological Engineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 19.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hualan Biological Engineering's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.71%.


Hualan Biological Engineering EBIT Historical Data

The historical data trend for Hualan Biological Engineering's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering EBIT Chart

Hualan Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,617.31 2,152.35 1,709.97 1,458.63 2,090.82

Hualan Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 456.52 240.28 866.10 527.91 332.88

Competitive Comparison of Hualan Biological Engineering's EBIT

For the Biotechnology subindustry, Hualan Biological Engineering's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's EV-to-EBIT falls into.



Hualan Biological Engineering EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,967 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Engineering  (SZSE:002007) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hualan Biological Engineering's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1001.9 * ( 1 - 16.45% )/( (11425.275 + 10598.916)/ 2 )
=837.08745/11012.0955
=7.60 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16105.783 - 1571.915 - ( 3108.593 - max(0, 2581.451 - 9326.542+3108.593))
=11425.275

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16268.788 - 1350.504 - ( 4319.368 - max(0, 2460.945 - 9856.286+4319.368))
=10598.916

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hualan Biological Engineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1331.512/( ( (2726.099 + max(4336.691, 0)) + (2778.275 + max(4013.429, 0)) )/ 2 )
=1331.512/( ( 7062.79 + 6791.704 )/ 2 )
=1331.512/6927.247
=19.22 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2295.645 + 1673.627 + 1948.164) - (1571.915 + 0 + 8.8299999999999)
=4336.691

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2103.542 + 1923.371 + 1347.461) - (1350.504 + 0 + 10.441)
=4013.429

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hualan Biological Engineering's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=1967.175/29323.871
=6.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Engineering EBIT Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering (SZSE:002007) Business Description

Traded in Other Exchanges
N/A
Address
No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
An Kang Directors, executives
Pan Ruo Wen Executives
An Wen Qi Executives
Wang Qi Ping Directors, executives
Fan Bei Directors, executives
Ma Xiao Wei Executives
Xie Jun Min Directors, executives
Zhang Bao Xian Executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors
Sun Zhen Guo Supervisors
Chen Lei Shan Supervisors
Yang Bao Ping Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines